Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2011

View Archived Issues

Scientists at Novartis and IRM present novel B-raf inhibitors

Preclinical antitumor activity reported for (R)-bicalutamide derivatives ISIR-9 and ISIR-11

Amplified DNA sequences and retrotransposon elements identified in tumor-released microvesicles

Antisense oligonucleotide ASO 10-27 alleviates symptoms of severe muscular atrophy in vivo

RAGE antagonist CKH-66 reduces brain beta-amyloid in vivo

Oncolytic herpes simplex virus safe and feasible in patients with advanced pancreatic cancer

Modified aminoglycosides designed for nonsense suppression therapy in genetic diseases

Modulators of cell cycle checkpoints patented by Merck & Co.

U.S. researchers synthesize novel 15-LOX inhibitors

Lundbeck updates recent pipeline progress

New DPP IV inhibitors reported by Merck & Co.

Scientists at Takeda present new mTOR inhibitors for cancer and other disorders

Novel beta-secretase inhibitors patented jointly by Roche and Siena Biotech

Adocia's phase I HinsBet study shows encouraging results in diabetes

CytRx begins phase Ib INNO-206 study in advanced solid tumors

Fibrocell Science provides FDA final data from azficel-T histology study

ExonHit's AclarusDx receives CE marking for diagnosis of Alzheimer's

Senesco's study of SNS01-T in multiple myeloma on hold by FDA

Ariad and Merck & Co. to copromote ridaforolimus for sarcoma in U.S.

NicOx grants Ferrer option for osteoarthritis candidate naproxcinod

TaiMed Biologics and Ambrilia sign worldwide agreement for HIV programs

Anacor and Medicines for Malaria Venture agree to jointly develop AN-3661

Antisense Therapeutics continues seeking partner for ATL-1101 in prostate cancer

Phase II study with Stem Cell Therapeutics' prolactin starts in multiple sclerosis

Phase I trial of AZD-8055 in subjects with recurrent gliomas to begin this month

Anacor's phase IIb trial of AN-2728 in psoriasis reaches full enrollment

Kythera reports additional efficacy data from phase II trial of ATX-101 in submental fat

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Circulating sncRNA transcriptome in diabetic kidney disease and SGLT2 inhibitor treatment
BioWorld Science
Small noncoding RNAs (sncRNAs), including miRNAs, piRNAs and snoRNAs, can provide further biological insights into the mechanisms of chronic kidney disease (CKD)...